Overview

A Study of BBI503 in Adult Patients With Advanced Solid Tumors

Status:
Completed
Trial end date:
2020-06-01
Target enrollment:
Participant gender:
Summary
This is an open label, single arm dose escalation study of BBI503 in adult patients with advanced solid tumors.
Phase:
Phase 1
Details
Lead Sponsor:
Boston Biomedical, Inc
Sumitomo Dainippon Pharma Oncology, Inc